Compare IMMR & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IMMR | ACOG |
|---|---|---|
| Founded | 1993 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 241.4M | 193.6M |
| IPO Year | 1999 | 2024 |
| Metric | IMMR | ACOG |
|---|---|---|
| Price | $7.18 | $8.33 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $18.00 |
| AVG Volume (30 Days) | ★ 347.1K | 88.2K |
| Earning Date | 09-14-2026 | 11-12-2026 |
| Dividend Yield | ★ 4.17% | N/A |
| EPS Growth | N/A | ★ 41.58 |
| EPS | ★ 0.17 | N/A |
| Revenue | ★ $35,013,000.00 | $10,220,275.00 |
| Revenue This Year | N/A | $153.87 |
| Revenue Next Year | N/A | $85.66 |
| P/E Ratio | $42.38 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.25 | $4.50 |
| 52 Week High | $8.05 | $10.14 |
| Indicator | IMMR | ACOG |
|---|---|---|
| Relative Strength Index (RSI) | 46.99 | 41.03 |
| Support Level | $7.09 | $8.30 |
| Resistance Level | $7.64 | $9.48 |
| Average True Range (ATR) | 0.18 | 0.43 |
| MACD | -0.00 | -0.05 |
| Stochastic Oscillator | 36.23 | 21.29 |
Immersion Corp is a licensing company focused on the acceleration, and scaling, through licensing, of haptic technologies that allow people to use sense of touch to engage with products and experience the digital world around them. Its patents cover a wide range of digital technologies and ways in which touch-related technology can be incorporated into and between hardware products and components, systems software, application software, and digital content. It operates in two operating segments: Immersion and Barnes & Noble Education. The majority of revenue is derived from Barnes & Noble Education segment which is a contract operator of physical and virtual bookstores for college and university campuses and K-12 institutions across the United States.
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimers disease, for which there are limited or no treatment options. The Companies current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Companies commercial development program for ZUNVEYL is focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.